New Editors-in-Chief  for ESMO Journals 2026

The European Society for Medical Oncology (ESMO) has announced new leadership appointments across its journals, reflecting the Society’s continued commitment to excellence in scientific publishing and its dedication to advancing global oncology research. The changes will take effect in January 2026.

Editor-in-Chief ESMO Open

Dr. Hope S. Rugo has been named the next Editor-in-Chief of ESMO Open, succeeding Professor Giuseppe Curigliano, who has led the journal since its inception. Dr. Rugo’s appointment marks a milestone in ESMO’s history, as she becomes the first standalone female Editor-in-Chief of an ESMO journal.

Images

Name

Dr. Hope Rugo is the Division Chief of Breast Medical Oncology and Director of the Women’s Cancers Program at City of Hope, California, and a leading figure in breast cancer research worldwide. Her work has been instrumental in shaping the development of novel therapies and clinical trial design in breast oncology. With an extensive record of publications and leadership in international collaborations, she has contributed significantly to advancing translational science and improving outcomes for patients with breast cancer.

Under Dr. Rugo’s leadership, ESMO Open is expected to continue expanding its role as a leading open-access platform for oncology research, fostering the dissemination of high-quality evidence, reviews, and expert perspectives that bridge the gap between scientific discovery and clinical application.

Co-Editors-in-Chief ESMO Immuno-Oncology and Technology (IOTECH)

Professors John Haanen and Sherene Loi have been appointed as Co-Editors-in-Chief of ESMO Immuno-Oncology and Technology (IOTECH) for the 2026–2027 term, succeeding the current editorial leadership. Their joint appointment brings together two internationally recognized experts with complementary expertise in immuno-oncology, translational research, and clinical innovation.

Images	Name
	Professors John Haanen, from the Netherlands Cancer Institute, is a leading authority in cancer immunotherapy and cellular therapy. He has made major contributions to the development of T-cell-based treatments and the clinical translation of immune checkpoint inhibitors. Beyond his scientific achievements, he has been actively involved in ESMO’s academic and educational initiatives, contributing to the Society’s strategic direction in immuno-oncology.
	Professor Sherene Loi, based at the Peter MacCallum Cancer Centre and the University of Melbourne, is globally recognized for her work in breast cancer immunology and genomics. Her pioneering research on tumour-infiltrating lymphocytes (TILs) and biomarkers for immunotherapy responsiveness has significantly influenced the integration of immune approaches in breast cancer management.

Together, Professors Haanen and Loi will guide IOTECH in its mission to serve as a leading interdisciplinary platform at the interface of immunotherapy, oncology, and technology, promoting the publication of high-impact research that drives clinical innovation and improves patient outcomes. Their combined expertise and leadership are expected to strengthen the journal’s position as a central resource for the evolving field of immuno-oncology.

A New Chapter in ESMO Publishing

Through these appointments, ESMO reinforces its commitment to supporting global oncology scholarship and nurturing editorial leadership that reflects the diversity and excellence of the oncology community. The new Editors-in-Chief bring not only outstanding scientific credentials but also a shared vision for advancing collaboration, inclusivity, and innovation across ESMO’s publications.

More posts featuring ESMO 

Written by Nare Hovhannisyan, MD